Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release
- 1 January 2004
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 113 (3-4) , 225-233
- https://doi.org/10.1016/j.thromres.2004.02.018
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Platelet Glycoprotein IIb/IIIa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery DiseaseCirculation, 2003
- Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitroThrombosis Research, 2003
- Intrinsic Activating Properties of GP IIb/IIIa BlockersThrombosis Research, 2001
- Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromesJournal of the American College of Cardiology, 2000
- Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) TrialCirculation, 2000
- Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart DiseaseCirculation, 1998
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Nitric oxide released from activated platelets inhibits platelet recruitment.Journal of Clinical Investigation, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997